COVID-19 Syrian hamster model

Services

We are ready to answer your questions and provide guidance.

covid-19 Syrian hamster model

 

IITRI has developed a robust model for COVID-19 using the Syrian (golden) hamster.

Below is a basic study description and design, although IITRI can provide specialized study designs based on your needs. Contact us today to learn more and discuss how we can partner for SARS-CoV-2 animal studies.

 

Species Information Syrian Hamster (~5-6 weeks at challenge)
Study Duration Sponsor dependent (14+ normal)
Challenge Dosage and Strains

Intranasal (25 μl / nare) at  5 x 10^4; wildtype USA-WA1/2020),  relevant variants

Drug administration Aerosol, PO, IN, SC (inquire about others)

 

 Study Details

ID50=2-5E2 TCID50, recommended 5-10xID50= 1-5E3to4 TCID50

Primary readouts

  • Viral load in lungs
    • TCID50 (infectious virus). Starts on Day 1, peaks on Day 2-3
    • RT-qPCR (prescence of genomic viral RNA). Starts on Day 1, peaks on Day 2-3
    • RT-qPCR (active viral replication/transcription).
  • Viral load in upper respiratory tract
    • TCID50 (infectious virus). Starts on Day 1, peaks on Day 2-3. Undetectable/inconsistent after Day 4
    • RT-qPCR (prescence of genomic viral RNA). Starts on Day 1, peaks on Day 2-3. Inconsistent. 
    • RT-qPCR (active viral replication/transcription). 
  • Viral load in swabs (virus shedding)
    • TCID50 (infectious virus). Starts on Day 1, peaks on Day 2-3
    • RT-qPCR (prescence of genomic viral RNA). Starts on Day 1, peaks on Day 2-3, lingers until > Day 10

Secondary readouts

  • Body weigh loss 4-10%. Starts on Day 2, peak on Day 7-8 and then they recovered. 
  • Cytokines by RT-qPCR (gene expression)
  • Histopathology of lungs. Day 2-3 (peak of disease) vs Day 7 (peribronchiolar metaplasia or lambertosis, sequelae)